Regeneron Pharmaceuticals Inc. (REGN)

Common-Size Income Statement
Quarterly Data

Low level of difficulty

Regeneron Pharmaceuticals Inc., common-size consolidated income statement (quarterly data)

	3 months ended	Sep 30, 2019		Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Net product sales
	Sanofi collaboration revenue
	Bayer collaboration revenue
	Other revenue
	Revenues
	Cost of goods sold
	Cost of collaboration and contract manufacturing
	Cost of revenues
	Gross profit
	Research and development
	Selling, general, and administrative
	Income from operations
	Other income (expense), net
	Interest expense
	Other income (expense)
	Income before income taxes
	Income tax expense
	Net income

Income statement item	Description	The company
Income from operations	The net result for the period of deducting operating expenses from operating revenues.	Regeneron Pharmaceuticals Inc.’s income from operations as a percentage of revenues declined from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.
Income before income taxes	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Regeneron Pharmaceuticals Inc.’s income before income taxes as a percentage of revenues declined from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.
Net income	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Regeneron Pharmaceuticals Inc.’s net income as a percentage of revenues declined from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.

	Regeneron Pharmaceuticals Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality